R&D

Opening New Possibilities in Therapeutics for Hard-to-Treat Solid Tumors

Cross-Ministerial Partnerships

Cross-Ministerial Funding Program (Since 2025)
Building a centralized supply system for clinical research materials and advancing full-stage immune cell gene therapy development through cross-ministerial collaboration.
Program
CAR-X Platform Technologies for Solid Tumor Therapy
Objective
Developing platform technologies for CAR-X therapies that selectively target solid tumors.
Viral Vector & T Cell Manufacturing
Clinical Research Planning Support
Ministry of
Science and ICT
(National Research
Foundation
of Korea)
Basic & Platform
Technology Development
Next-generation CAR platform technologies for solid tumor therapy
  • Gene delivery and tumor microenvironment
  • Switchable and controllable CAR technologies
National
Cancer Center
(NCC)
Supported by
the Ministry
of Health and
Welfare
Early Clinical Development
National R&D Program for Full-Stage Development of Immune Cell and Gene Therapy
  • Supporting advanced regenerative medicine clinical research
    (CAR-T / TCR-T / TIL)
Ministry of Food
and Drug Safety
(Korea Health
Industry
Development
Institute)
Regulatory Readiness
Evaluation technologies for the quality, safety, and efficacy of TCR-T and TIL therapies
Viral Vector & T Cell Manufacturing
Clinical Research Planning Support
Ministry of
Science and ICT
(National Research
Foundation
of Korea)
National Cancer
Center (NCC)
Supported by
the Ministry
of Health
and Welfare
Ministry of Food
and Drug Safety
(Korea Health
Industry
Development
Institute)
National Cancer Center (NCC)
Supported by the Ministry of Health and Welfare
Early Clinical Development

National R&D Program for Full-Stage Development of Immune Cell and Gene Therapy

  • Supporting advanced regenerative medicine clinical research (CAR-T / TCR-T / TIL)
Ministry of Science and ICT
(National Research Foundation of Korea)
Basic & Platform Technology Development

Next-generation CAR platform technologies for solid tumor therapy

  • Gene delivery and tumor microenvironment
  • Switchable and controllable CAR technologies
Ministry of Food and Drug Safety
(Korea Health Industry Development Institute)
Regulatory Readiness

Evaluation technologies for the quality, safety, and efficacy of TCR-T and TIL therapies

Strategy
Manufacturing and Supply of Clinical Research Materials and Sharing of Research Outputs
  • Viral Vector
    and T Cell Manufacturing
  • CAR-T/TCR-T
    Clinical Research
  • Neoantigen-Reactive
    TIL Clinical Research
CAR-T/TCR-T Clinical Research
NCC
GMP Manufacturing of Viral Vectors
GMP Manufacturing of CAR-T and TCR-T Cells
Researchers
Advanced Regenerative
Medicine Clinical Research
  • Shared CMC Knowledge Base
TIL Clinical Research
NCC
Initial TIL Culture
GMP Manufacturing
NCC Researchers
Tumor Tissue Collection
Basket Clinical Research
  • Neoantigen-Specific TCR Patents
  • TCR Database